COMP <GO>
ELMD vs MRK // PIOTROSKI F-SCORE QUALITY
Electromed Inc. (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: ELMD 6
— MRK 7
▲ PIOTROSKI F-SCORE QUALITY LEADER: ELMD
LAST: $27.04 (-2.31%) • MKT CAP: $229.4M
piotroski-score
8/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELMD VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELMD | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.10% | 74.80% | +3.30 | ELMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 24.10% | 20.70% | +3.40 | ELMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.8x | 15.3x | +6.50 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 4.85% | 3.42% | +1.43 | ELMD | /fcf-yield <GO> |
| Operating Margin | 15.10% | 34.30% | -19.20 | MRK | /operating-margins <GO> |
| Net Profit Margin | 11.80% | 28.10% | -16.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 17.00% | 1.30% | +15.70 | ELMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 17.64 | 5.19 | +12.45 | ELMD | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 7/9 | +1.00 | ELMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.8 | 51.7 | -2.90 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.5x | 18.4x | +7.10 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $229.4M | $361.02B | -$360.79B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELMD REV | MRK REV | ELMD GROSS % | MRK GROSS % | ELMD FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $64.0M | $65.01B | 78.1% | 74.8% | $11.1M | $12.36B |
| FY 2024 | $54.7M | $64.17B | 76.3% | 76.3% | $8.8M | $18.10B |
| FY 2023 | $48.1M | $60.12B | — | — | $1.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELMD // BETA —
MRK // BETA 0.92